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Transthyretin related amyloidosis (ATTR) results from the tissue deposition of 
misfolded mutant or wild-type transthyretin (TTR). Involvement of nervous system 
often heralds the onset of ATTR. Familial ATTR is because of mutations in the TTR 
gene which lead to destabilization of the tetrameric structure of TTR and generation 
of amyloidogenic monomers, tissue deposition of which causes end organ injury 
specially neuropathy and cardiomyopathy. Peripheral neuropathy is typically axonal 
with early involvement of the autonomic nerves. Wild-type TTR (ATTRwt), is a com-
mon cause of cardiomyopathy in the elderly and may play a role in the pathogenesis 
of carpal tunnel syndrome and spinal stenosis in that age group. Diagnosis of ATTR is 
made by demonstrating tissue amyloid deposits, then proving that the amyloid depos-
its consist of mutant or wild-type TTR, which necessitates assessment of TTR gene 
sequencing. Disease modifying treatments have become available for ATTR through 
liver transplantation, stabilization of the TTR molecule (diflunisal and tafamidis) and 
suppressing the gene expression of TTR (inotersen and patisiran).
Keywords: TTR, ATTR, transthyretin amyloidosis, ATTRwt, tafamidis, diflunisal, 
inotersen, patisiran
1. Introduction
Systemic amyloidosis comprises a group of diseases characterized by deposi-
tion of misfolded proteins which express abnormal β-sheet conformation usually 
in the extracellular spaces in different tissues [1]. At least 36 amyloid precur-
sor proteins are recognized so far in the humans [2]. There are several general 
pathogenetic pathways that proteins become misfolded and create amyloid fibrils 
[3]: (1) presence of abnormal protein such as amyloid light chain (AL) or those 
caused by a mutation (such as familial ATTR and amyloidosis related to gelsolin 
mutations), (2) prolonged exposure to a normal protein such as systemic reac-
tive (AA) and dialysis related amyloidosis; and (3) age related amyloidosis such 
as senile systemic amyloidosis. This book chapter will discuss the neurological 
manifestations of familial and wild-type ATTR, their diagnosis and treatment. 
Although neuropathy related to familial ATTR is uncommon, it is underdiagnosed 
and causes profound disability and mortality, largely as a result of concomitant 
cardiomyopathy. Timely diagnosis and treatment improves the outcome as new 




TTR is a 127 amino acid protein, is encoded by 7 kb of DNA spanning exons 
1–4 of a single gene on chromosome 18 [4]. TTR is a carrier molecule of thyroxine 
and vitamin A. Serum TTR is synthesized and excreted by the liver as a tetrameric 
structure. Other sources of local TTR synthesis include epithelial cells of the 
choroid plexus and the retinal pigment epithelium. TTR is however dispensable 
for thyroid hormone homeostasis; TTR knockout mice are euthyroid and have 
a normal phenotype [5, 6]. The presence of point mutations in TTR results in 
destabilization of the tetramere, and dissociation into amyloidogenic monomers, 
which misfold and self-aggregate into insoluble amyloid fibrils (Figure 1). Two 
distinct types of amyloid fibrils have been described in TTR amyloid deposits: 
type A, consists of C-terminal TTR fragments and full-length TTR, and type B, 
which only consists of full-length TTR [7]. Type A fibrils often target the heart 
and type B fibrils occur predominantly with neurological symptoms [8]. Every 
organ of an individual patient contains the same (either type A or type B) fibrils, 
and the composition is unchanged over time. The presence of C-terminal TTR 
fragments has an impact on the affinity for various tracers used for intensity of 
tissue Congo red staining and of noninvasive imaging of amyloid depositions 
using 99 m-technetium-diphosphono-propanodicarboxylic acid scintigraphy [7].
3. Familial transthyretin related amyloidosis (fATTR)
fATTR is a multisystem disease involving the heart (cardiomyopathy, conduc-
tion disturbances), gastrointestinal tract, kidneys, thyroid, salivary glands, eyes, 
peripheral and central nervous system. More than 130 pathological mutations have 
been associated with fATTR [9, 10].
Figure 1. 
Amyloid formation by TTR requires rate-limiting tetramer dissociation to a pair of folded dimers, which 
then quickly dissociate into folded monomers. Partial unfolding of the monomers yields the aggregation-prone 
amyloidogenic intermediate. The amyloidogenic intermediate can misassemble to form a variety of aggregate 
morphologies, including spherical oligomers, amorphous aggregates, and fibrils. Tafamidis binding to the TTR 
tetramer (upper left, see text below) dramatically slows dissociation, thereby efficiently inhibiting aggregation 
[from [63], with permission].
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3.1 Epidemiology
There is a marked variation in the prevalence and age of onset of ATTR in 
different countries, partly as a result of variation in the type of pathogenic muta-
tion. fATTR is endemic in northern Portugal, Sweden and Japan, but sporadically 
occurs everywhere in the globe, with estimated number of about 5–10,000 patients 
worldwide [11]. The global prevalence is estimated at 0.87–1.1 per million; preva-
lence in Europe and Japan are estimated at 1/100,000 and 1 per million individuals 
respectively [12, 13]. The age of onset has a wide range, between 10s and 90s [10]. In 
Japan, the age of onset is bimodal, with early (30–40 year old) and late (60s) onset 
peaks [10]; on the other hand, the age of onset is more likely to be early (25–35 years 
old) in Portugal and late in Sweden [14, 15]. The most common mutation associ-
ated with familial amyloid polyneuropathy (FAP) is Val30Met mutation (replace-
ment of valine with methionine at position 30), with endemic spots in northern 
Portugal (where its prevalence is estimated at 1/538), Sweden, Japan, and Brazil. 
On the other hand, the most common mutation in the US metropolitan areas is 
Val122Ile (isoleucine is substituted for valine at position 122); this mutation almost 
exclusively occurs in patients of African descent and has he allele prevalence of 
0.0173; i.e. 3.43% of African Americans carry at least one copy of the mutant gene 
[16]. Val122Ile related fATTR generally has a cardiac phenotype. In the UK popula-
tion the majority of patients have the T60A missense mutation where tyrosine is 
replaced by adenine at position 60. This has been traced to a single founder muta-
tion from north-west Ireland [17].
3.2 Neurological manifestations
Depending on the mutation in TTR, the phenotype can be cardiologic, neuro-
logic, or mixed. Neurological manifestations, particularly polyneuropathy are the 
most common manifestations of some of the mutations.
3.2.1 Familial amyloid polyneuropathy (FAP)
FAP is the most common neurological manifestation of fATTR. It is autosomal 
dominant, but the penetrance is variable and dependent on the type of mutation. 
If untreated, patients will have progressive neuropathy and disability resulting 
in death 10–15 years after disease onset [18]. The Val30Met mutation is the most 
common mutation associated with FAP, with a variable disease phenotype. Early 
onset disease (age < 50), which is more common in endemic regions of Japan and 
Portugal has a high penetrance and presents with a progressive polyneuropathy 
predominantly involving the small fiber nerves, which is typically manifested 
by loss of distal pain and temperature sensation, and progressive autonomic 
dysfunction; the latter includes orthostatic hypotension, neurogenic bladder, 
erectile dysfunction and impaired bowel function (malabsorption, diarrhea and 
constipation), and the presence of cardiac conduction blocks often necessitate 
pacemaker placement [10, 19]. On the other hand, late onset (>50 year old) phe-
notype, which occurs in non-endemic regions of Portugal, Sweden and Japan and 
sporadic cases in other parts of the world, is characterized by a low penetrance 
rate, male sex predominance. Late onset cases may not have significant clinical 
dysautonomia, and often present with a progressive distal neuropathy involving 
large and small fiber modalities, presenting with motor weakness and loss of 
vibratory and position sense early on, often with significant neuropathic pain. 
Autonomic dysfunction was the initial manifestation of 48% of early onset and 
10% of late onset FAP in a previous study [20]. Late onset FAP is often misdiag-
nosed for more common entities in that age group such as idiopathic neuropathy 
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or chronic inflammatory demyelinating polyneuropathy (CIDP) partly because 
of lack of positive family history and autonomic symptoms [9, 19, 21]. Other 
reasons for misdiagnosis include presence of demyelinating features in the nerve 
conduction study, elevated cerebrospinal fluid (CSF) protein level [22, 23], 
and negative abdominal fat pad a nerve biopsy for Congo-red amyloid stain-
ing [9]. In a previous study on patients with familial amyloid cardiomyopathy, 
abdominal fat pad and bone marrow biopsy showed amyloid deposits in 67 and 
41% of the patients respectively, while a sural nerve biopsy was positive in 83% 
of the patients who had that procedure [27]. It is therefore very important to do 
an amyloidosis workup, including echocardiography, nuclear imaging studies, 
and nerve biopsy on CIDP patients who do not respond to immunomodulatory 
treatment [9, 22, 23]. Val122Ile is the most common fATTR mutation in the USA, 
and usually has a cardiac phenotype, rather similar to ATTRwt (see below) [24, 
25]; but carpal tunnel syndrome is rather common and neuropathy has also been 
reported in Val122Ile ATTR [26]. Unusual neuropathy phenotypes of FAP include 
upper extremity onset, ataxic and motor predominant [13]. For example, FAP 
associated with T60A mutation (which one of the more common mutations in 
UK) is characterized by a non-length dependent sensory loss and motor deficits, 
often rapidly progressive disease, and lack of positive sensory symptoms [17]. 
There is a diagnostic delay of up to 4 years for FAP diagnosis, especially when 
the autonomic symptoms are lacking [9, 21, 27]; As effective treatments are now 
available for FAP, it is very important to diagnose it in early stages, and before the 
cardiovascular and neurological disability are not severe. Presence of “red-flag” 
symptomatology have been emphasized to expedite the diagnosis, these include 
positive family history for neuropathy, unexplained heart disease including but 
not limited to atrial fibrillation, cardiac hypertrophy on echocardiography, carpal 
tunnel syndrome, gastrointestinal symptoms (anorexia, constipation, diarrhea, 
nausea, vomiting and unexplained weight loss, alternating constipation and 
diarrhea), renal involvement (proteinuria and renal failure) and ocular disease. 
The presence of >1 of the aforementioned features should prompt genetic test-
ing for fATTR, as well as neurological and cardiovascular workup directed at 
the detection of amyloidosis [10, 28]. Gene sequencing has become increasingly 
affordable, and currently can be done free of charge for some patients in the USA 
(www.invitae.com/en/alnylam-act-hattr-amyloidosis; www.ambrygen.com/part-
ners/hattr-compass/healthcare-provider). Another rather common diagnostic 
challenge is differentiating ATTR from primary (AL) amyloidosis. Monoclonal 
gammopathy of unclear significance (MGUS) has been reported in ~20–50% 
of patients with ATTR cardiomyopathy [29, 30]. Very high (>5.0) or low (<0.2) 
kappa/lambda ratio usually imply AL amyloidosis whereas normal ratio (0.7–1.2) 
suggests ATTR [31]. Sometimes, however, the result of kappa/lambda ratio is 
inconclusive. Immunohistochemistry (IHC), i.e. staining of amyloid deposits 
with antibodies to kappa and lambda light chains as well as TTR can be used to 
make the differentiation between AL amyloidosis and ATTR, however, amyloid 
subtype cannot be determined in 20–25% of cases with IHC alone [32]. Laser 
capture microdissection of amyloid deposits (microdissection done on Congo 
red stained tissue materials) followed by mass spectroscopy has increased the 
sensitivity and specificity of amyloid subtyping to 98–100% [32, 33] (Figure 2). 
Lipid chromatography-tandem mass spectrometry (LC-MS/MS) is another, more 
recent technology which determines the presence of mutant peptides with rather 
high accuracy [33–35]. However, LC-MS/MS had a sensitivity of 84% in picking 
up mutations that were detected in the genetic testing in a recent US study on 
56 patients with fATTR cardiomyopathy [36]. Eight of the nine patients with 
mismatch between genetic testing and LC-MS/MS in the aforementioned study 
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were African Americans, two of whom were homozygote to Val122Ile mutation. 
Sensitivity of LC-MS/MS to pick up mutations is diminished in instances that 
mutation does not result in significant mass shift, or is located in regions of the 
gene with short tryptic peptides [34, 37]. Nuclear imaging studies, using bone 
avid tracers 99mTc-DPD (technetium-3,3-diphosphono-1,2-propanodicar-
boxylic acid), 99mTc-PYP (technetium-pyrophosphate) and 99mTc-HMDP 
(technetium-hydroxymethylene diphosphonate) have been increasingly used to 
diagnose ATTR related cardiomyopathy as they are widely available, have good 
sensitivity and are not costly [38, 39]. Demonstration of cardiac uptake using the 
aforementioned methods in a patient with neuropathy and heart disease strongly 
suggests ATTR if AL amyloidosis is excluded using serum and urine immunoelec-
trophoresis/immunofixation and assessment of serum free light chains [29].
3.2.2 Familial leptomeningeal and oculomeningeal amyloidosis
Leptomeningeal and meningovascular amyloidosis, often with concomitant 
vitreous opacity, are rare neurological manifestations of fATTR. Leptomeningeal 
amyloidosis has been reported with different TTR mutations (Val30Met, Val30Gly, 
Leu12Pro, Phe64Ser, Ala36Pro, Gly53Glu, Tyr69His, Ala25Thr, Tyr114Cys, 
Asp18Gly), sometimes in combination with FAP [40–47]. CNS symptoms include 
stroke, subarachnoid hemorrhage, dementia, hydrocephalus, ataxia, seizures, and 
sensorineural hearing loss. MRI studies may demonstrate leptomeningeal enhance-
ment and superficial siderosis (sequela of intracranial bleedings) and there may be 
markedly elevated CSF protein [46, 48]. Ocular and meningovascular manifesta-
tions are specially common after liver transplantation, as the patient lives longer 
and mutant TTR is still being ecreted from the retinal cells and choroid plexus [49]. 
A previous study demonstrated that 27/87 (31%) of patients with Val30Met related 
FAP had focal neurological episodes, which occurred on average >14 years after the 
onset of FAP; more common after liver transplantation but also in patients with 
milder phenotypes which have a longer survival [47].
Figure 2. 
Laser microdissection of amyloid deposits and mass spectroscopy. (a) Congo red-stained section of the 
postmortem heart specimen viewed under fluorescent light source. Bright red areas represent amyloid 
deposits. Areas microdissected for mass spectrometry-based proteomic analysis are indicated by purple-
colored lines. (b) The results of mass spectrometry-based proteomics analysis of amyloid plaques obtained by 
microdissection. The identified proteins are listed according to the relative abundance they were represented 
in two independent microdissections. The top 10 proteins are shown. The columns show the protein name, 
the UnitProt identifier (protein accession number in the UniProt database, http://www.uniprot.org/), the 
molecular weight of the protein (MW) and two microdissections (S1-S2). The numbers indicate number 
of total peptide spectra identified for each protein. The most abundant protein is TTR. Apolipoprotein 
E, serum amyloid P-component and apolipoprotein A-IV are constituents of many amyloid types. In 




3.3 Treatment of familial ATTR
Disease modifying treatments have become available for FAP since 1990s, start-
ing with liver transplantation (Figure 3). Treatment strategies include: (1), deplet-
ing the source of mutant TTR (liver transplantation); (2), inhibition of formation 
of TTR (wild type and mutant), by preventing translation of mRNA with antisense 
oligonucleotide (ASO) or with small interfering RNA (siRNA) technologies;  
(3), stabilization of TTR tetramere by small molecules (diflunisal and tafamidis); 
and (4), therapy directed to remove the amyloid deposits [19]. Currently approved 
disease modifying treatments by US food and drug administration (FDA) include 
inotersen and patisiran; with tafamidis approval under FDA review.
3.3.1 Liver transplantation
Removing the source of mutant TTR (liver) was the first disease modifying 
treatment for FAP. Liver transplantation, however, involves a major surgery, which 
is not tolerated with patients with significant underlying cardiovascular disease, and 
necessitates lifelong immunosuppression. Overall 5 year survival after liver trans-
plantation is ~80% [50]. The 5 and 10 years survival rates post- transplantation were 
significantly better after Val30Met cases (82 and 74%) than the other mutations  
[50, 51]. Cardiomyopathy is a major determinant of prognosis with 10-year survival 
rates of 92 and 64% post-transplantation for patients without and with cardiomyop-
athy in a previous study [52]. Furthermore, liver transplant is more effective in chang-
ing the natural course of the disease in early onset Val30Met than the late onset cases, 
which could be due to more severe cardiomyopathy in the latter subtype [53]. Liver 
transplant is not an effective treatment for ATTRwt, leptomeningeal and ocular amy-
loidosis. Although ~90% of patients with early sensory neuropathy demonstrate disease 
stability after a liver transplant, organ involvement is not usually reversed, furthermore, 
FAP, and specially cardiomyopathy often deteriorate gradually post-transplant  
due to the deposition of ATTRwt [54, 55]. Advanced age and malnutrition are also 
risk factors for poor outcome/survival after liver transplantation [53, 56], partly 
because there is more predisposition to deposition of wild-type TTR in older age. 
Figure 3. 
Treatment strategies for fATTR (modified, from [92], with permission).
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Combined liver-kidney or liver-heart, and rarely liver-heart-kidney transplantation 
has been used for FAP patients with advanced renal or heart disease [55].
3.3.2 Stabilizers of TTR tetramere
Nonsteroidal anti-inflammatory drugs (NSAIDs) and tafamidis meglumine 
inhibit TTR tetramere degradation and therefore formation of amyloidogenic 
monomers. NSAIDs have structural resemblance to thyroxine, a natural tetramere 
stabilizer. Diflunisal and tafamidis are disease modifying treatments for fATTR.
3.3.2.1 Diflunisal
In a randomized, double blinded, placebo controlled trial on 130 patients with 
FAP, diflunisal 250 mg twice a day was well tolerated and slowed the progression of 
neuropathy over a period of 2 years [57]. In that study, the Neuropathy Impairment 
+7 (NIS + 7) score increased by an average of 25.0 points in the placebo group versus 
8.7 points in the diflunisal group (increase indicates deterioration of neuropathy). 
On the other hand, diflunisal also had a favorable effect on the quality of life; 
average of 36-Item Short-Form Health Survey (SF-36) physical scores decreased by 
4.9 points in the placebo group and increased by 1.5 points in the diflunisal group. 
Modified body mass index (BMI), the product of serum albumin concentration 
(measured in grams per liter) and BMI (calculated as weight in kilograms divided 
by height in meters squared), which is an indicator of malnutrition and correlates 
with survival in FAP [58, 59], was the only endpoint which did not show improve-
ment with diflunisal. In another study on 40 Japanese patients with fATTR, diflu-
nisal was effective on neurological and cardiological manifestations after a period 
of 24 months, 3 patients could not tolerate diflunisal because of declining renal 
function or thrombocytopenia [60]. Diflunisal is inexpensive and widely available, 
but some of the potential problems associated with NSAIDs in general, such as 
gastrointestinal adverse effects including bleeding, limit its use, and caution is to be 
exercised in its use in the setting of underlying heart or kidney disease [61].
3.3.2.2 Tafamidis (Vyndaqel)
Tafamidis was the approved in European Union in 2011, for adult patients with 
early FAP regardless of the type of mutation [12]. It has since also been approved 
in Argentina, Japan and Mexico, for delaying the neurological disabilities of FAP 
[62]. Tafamidis binds selectively to the two normally unoccupied thyroxine-
binding sites of the tetramer, and kinetically stabilizes TTR, including the less 
stable mutant TTR tetramers, preventing the tetramer dissociation, which is the 
rate-limiting step in the generation of amyloidogenic monomers [63] (Figure 1). 
In a previous study, 98% of the patients had TTR stabilization after 18 months of 
tafamidis [64]. Tafamidis is more effective in early onset Val30Met cases than late 
onset Val30Met and non-Val3 Met mutations, there was progression of disability 
score in 55% and deterioration of neuropathy score of most of patients with late-
onset ATTR V30 M involved in a nonrandomized controlled trial [13]. In a double 
blinded multicenter study, tafamidis 20 mg per day, was compared to placebo in 
an 18-month study in adult patients with early-stage Val30Met TTR-FAP [64]. 
There were no statistically significant differences between tafamidis and placebo 
for the coprimary endpoints (changes of the Neuropathy Impairment Score-
Lower Limb (NIS-LL) and Norfolk Quality-of- Life (QOL) Diabetic-Neuropathy 
Questionnaire) in the intent to treat population, which included patients who 
dropped out for liver transplantation. On the other hand, in the efficacy evaluable 
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population, tafamidis patients had significantly better outcomes with the primary 
endpoints. Furthermore, tafamidis group had more favorable outcomes in the 
secondary endpoints which included changes in neurologic function, nutritional 
status, and TTR stabilization. Tafamidis is generally well tolerated including in 
long term, post-marketing, extension studies, with the majority of adverse effects 
of mild to moderate severity [64, 65].
3.3.3 Gene therapies
Inhibiting the transcription of TTR mRNA by gene silencing technologies such 
as antisense oligonucleotides (ASO) and small interfering RNAs (siRNA) constitute 
most promising approaches in the treatment of FAP. Inotersen and patisiran were 
approved by FDA in 2018.
3.3.3.1 Inotersen
Inotersen is a 2′-O-methoxyethyl-modified ASO, which selectively binds to the 
TTR complementary RNA and inhibits the liver synthesis of both wild-type and 
mutant TTR. In a double blinded 15 months study, NEURO-TTR, FAP patients in 
earlier neuropathy stages (ambulatory with or without assistance) received weekly 
subcutaneous injections of inotersen 300 mg after loading dose of 3 doses in the 
first week, versus placebo [66]. All of the patients also received daily Vitamin A 
supplementation 3000 IU. The serum TTR level in the inotersen group signifi-
cantly dropped from its baseline with a median nadir of 79.0% from week 13 to 
65. Inotersen recipients did significantly better in the primary endpoints: there 
was a difference in the least-square mean of 19.7 points in modified Neuropathy 
Impairment Score+7 (mNIS+7) and 11.7 points in Norfolk Quality of Life-Diabetic 
Neuropathy (QOL-DN), favoring inotersen group, after 66 weeks of treatment. 
Inotersen also slowed the weight loss with a statistical trend towards efficacy on 
decline of BMI. Improvement of the course of FAP and quality of life in the patients 
who received inotersen occurred regardless of the mutation type or the presence 
of cardiomyopathy. This study did not have sufficient power to assess efficacy of 
inotersen on cardiomyopathy. Significant side effects of inotersen included glomeru-
lonephritis and thrombocytopenia. 23% of inotersen recipients developed a platelet 
count below 100 × 109/L, and three patients had platelet counts to <25 × 109/L, one 
of whom died of brain hemorrhage. Antiplatelet antibodies were positive in all of the 
3 patients with severe thrombocytopenia pointing to the immune mediated nature 
of this complication. As thrombocytopenia associated with ASO treatment can be 
severe and fatal, platelet counts should be closely monitored in patients who receive 
inotersen. Patients who developed nephropathy had a crescentic glomerulonephritis 
on the background of amyloidosis, kidney function in one patients improved after 
treatment with prednisone and cyclophosphamide; therefore, monitoring of kidney 
function and urine protein are also necessary during treatment with inotersen. As a 
matter of fact, there was no additional cases of severe thrombocytopenia, and only 
a single patient developed a mild glomerulonephritis after the implementation of 
enhanced monitoring in the NEURO-TTR study. Local skin reactions were generally 
mild and did not result in discontinuation of the treatment in any patient.
3.3.3.2 Patisiran
Patisiran is a siRNA oligonucleotide wrapped in nanoparticles for specialized 
delivery to the liver, where it targets the 3′ untranslated region of TTR’s messenger 
RNA, resulting its cleavage, and therefore lack of transcription of TTR mRNA to 
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a protein product. Treatment with patisiran therefore results in reduction in the 
production of both wild-type and mutant TTR. After preliminary studies showed 
dose dependent reduction of serum TTR in normal subjects and patients with FAP 
who received patisiran, and possible favorable effect on the course of neuropathy in 
a phase 2 study [67, 68], a recent phase 3 double blinded (APOLLO) study compared 
patisiran 0.3 mg/kg every 3 weeks intravenously to placebo in patients with FAP [69]. 
Patients who had undergone liver transplantation or those with advanced heart failure 
were excluded. Treatment with patisiran resulted in sustained reduction of serum 
TTR over a period of 18 months (median 81%, range − 38–95). Patisiran recipients 
did significantly did better in all primary endpoints: the least-squares mean mNIS+7 
change from baseline was −6.0 in the patisiran versus + 28.0 in the placebo group (dif-
ference of 34.0 points favoring the patisiran group; P < 0.001) and the effect could 
be seen as early as 9 months; The least-squares mean change from baseline in Norfolk 
QOL-DN was −6.7 in patisiran versus 14.4 in the placebo group (difference, −21.1 
points, P < 0.001); patisiran recipients also did better with the modified BMI and gait 
speed. Fifty one percent of patients who received patisiran versus 10% of those on 
placebo had improvement in the Norfolk QOL-DN score after 18 months. Treatment 
efficacy included patients with Val30Met as well as other mutations, and included 
sensory, motor and autonomic aspects of neuropathy. Patients in the patisiran group 
also had better cardiac outcomes, i.e. changes in NT-proBNP, left ventricular wall 
thickness and longitudinal stress, than those on placebo. The side effects that were 
more common in the patisiran than the placebo included infusion-related reactions 
(19%) and peripheral edema (30%). Infusion reactions (back pain, flushing, abdomi-
nal pain, and nausea) were mild to moderate and only one patient dropped from 
the study as their result. Thrombocytopenia and nephropathy were not among the 
patisiran related side effects in that study.
3.3.4 Other potential treatments
A combination of doxycycline, which is proposed to disrupt deposited fibril-
lar TTR amyloid fibrils [19, 55, 70] and tauroursodeoxycholic acid (a biliary acid, 
and also a disrupter of nonfibrillar TTR) has been effective in removal of amyloid 
deposits in a mouse model [71]. Another promising approach to resolve existing 
amyloid deposits is targeting serum amyloid P (SAP) component, which has an avid 
binding to all amyloid fibril types, resulting in stabilization of the amyloid fibrils 
and preventing their proteolysis [72]; antibodies to SAP have been promising in 
animal models of amyloidosis [73], and are being investigated in different forms of 
human amyloidosis.
4. Wild-type ATTR (ATTRwt), aka. senile systemic amyloidosis
Systemic Deposition of ATTRwt is a rather common process associated with 
aging. Previous studies have reported a prevalence of 12–25% for tissue deposi-
tion of ATTRwt in people older than 80 year old [74, 75]. Despite very common 
prevalence in postmortem and tissue studies, ATTRwt is not a very recognized 
entity among the community physicians and therefore it is rather underdiagnosed. 
Patients with ATTRwt typically present with cardiac manifestations, including 
congestive heart failure, atrial fibrillation and other arrhythmias. ATTRwt is 
increasingly diagnosed as a cause of heart failure with preserved ejection fraction 
(HFpEF) [76]. Embolic evens are frequently encountered, mean survival period 
from the onset of congestive heart failure symptoms is ~75 months [19]. There are 
differences between fATTR and ATTRwt in the pattern and shape of tissue amyloid 
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deposition [74]. In fATTR deposits are predominantly localized in the pericardium 
and surrounding muscle fascicles, on the other hand, they have patchy plaque-like 
shapes and mostly appear inside the ventricular wall in ATTRwt cases. Differences 
also exist between the shape of deposited amyloid fibrils between fATTR and 
ATTRwt in electron microscopy: in fATTR, long, straight fibrils are arranged in par-
allel, whereas short, rigid fibrils with haphazard arrangement are noted in ATTRwt, 
with endocardial region more involved than epicardium [74]. ATTRwt also involves 
other organs, often subclinically. In the pathological study by Ueda, et al., amyloid 
deposits were noted in bladder in 5/6 cases; deposits in the thyroid, pancreas, liver, 
gallbladder, adrenal gland, and gastrointestinal tract were mainly located in the 
walls of small arteries [74].
4.1 Diagnosis of ATTRwt
It should be noted that significant amount of ATTRwt deposition, not a mere 
presence, is needed to establish a pathogenic role [77]. ATTRwt is most com-
monly diagnosed in the setting of a late onset cardiomyopathy. Tissue deposition 
of amyloid with Congo Red staining and subsequent immunohistochemical or 
proteomic analysis of the amyloid deposits along with a TTR gene sequencing 
(which does not show a pathogenic Mutation) are usually needed to diagnose 
ATTRwt. On the other hand, Technetium-labeled bone scintigraphy tracers are 
long to be known to be able to detect myocardial amyloid deposits, and use of 
this imaging modality for the diagnosis of cardiac ATTR amyloidosis has been 
increasingly. In a recent study on 857 patients with histologically proven cardiac 
amyloid (374 with endomyocardial biopsies) and 360 patients with nonamyloid 
cardiomyopathies, myocardial radiotracer uptake on bone scintigraphy was 
>99% sensitive and 86% specific for cardiac ATTR amyloid, with false positives 
exclusively due to cases with AL amyloidosis [29]. Therefore cardiac ATTR can 
be diagnosed without a tissue biopsy and exclusion of AL amyloidosis based on 
serum and urine immunofixation and free lambda and kappa levels. Similar to the 
situation with fATTR, high prevalence of MGUS in ATTRwt poses a diagnostic 
challenge. About one fourth to 50% of patients with ATTRwt have a monoclonal 
gammopathy in the serum or urine and ~10% have a high serum kappa/lambda 
ratio [30, 78, 79]. It should be noted that abdominal fat pad aspiration and biopsy 
have a low sensitivity for ATTRwt, 12–14% on some of the previous studies [80, 
81], although using abdominal fat pad biopsy, sensitivity of 73% has also been 
reported in another study [82].
4.2 Neurological manifestations of ATTRwt
ATTRwt is generally not associated with a polyneuropathy. A previous report 
suggested ATTRwt as a cause of a rapidly progressive neuropathy in an elderly 
woman; amyloid deposits were present in the gastrocnemius, but not the sural 
nerve of that patient [83]. On the other hand, ATTRwt is rather commonly 
associated with late onset musculoskeletal problems, particularly carpal tunnel 
syndrome and lumbar spinal stenosis, but overall it is underdiagnosed. ATTRwt 
deposits have been demonstrated in about one third of tenosynovial tissues 
obtained during carpal tunnel release operation in elderly patients [84, 85], as well 
as in 30–45% of the resected tissues harvested during decompression surgeries for 
lumbar spinal stenosis [77, 86].  
The ATTRwt deposits are frequently minimal and may not be important from 
the pathogenesis standpoint [77]. On the other hand, more prominent amyloid 
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deposition may play a role in spinal stenosis as they cause increased thickness 
of ligamentum flavum or abnormal spinal stability [86]. Examination of teno-
synovial tissue on 100 patients with idiopathic CTS showed positive Congo Red 
staining on 34 patients, all also positively staining with anti TTR antibody with 
negative gene sequencing, consistent with ATTRwt [84]. On the other hand, in 
a single center study involving 31 ATTRwt patients, CTS was the most common 
presenting symptom in more than 50% of the patients [87]. In another recent 
prospective study on 98 patients with idiopathic CTS in men >60 year and women 
>50, who underwent decompressive surgery, amyloid deposits were found in 10 
patients, 5 of which turned out to be due to ATTRwt [88]. Spinal cord compression 
secondary to ATTRwt has also been rarely reported [89, 90]. Myopathy is rarely 
reported as a feature of ATTRwt, but in the author’s opinion it is underdiagnosed. 
We previously reported a patient who presented with bent spine syndrome due 
to ATTRwt related myopathy affecting the thoracic paraspinal muscles [91]. That 
patient succumbed as the result of consequences of cardiomyopathy and a cardio-
embolic stroke.
4.3 Treatment of ATTRwt
Although TTR stabilizers and suppressors of gene expression will likely suppress 
ATTRwt deposition, there are no current FDA approved disease modifying therapies 
for ATTRwt and the management remains to be symptomatic, such as medical 
treatment of heart failure and arrhythmias, including insertion of defibrillator/
pacemaker, and heart transplantation if necessary. Treatment of neuromuscular 
complications remains to be symptomatic as well, i.e. decompression surgeries of 
myelopathy and lumbar spinal stenosis and carpal tunnel syndrome release. The 
reasons for lack of disease modifying treatments include the fact that ATTRwt 
is underdiagnosed and the natural history of its neuromuscular complications is 
unknown. Furthermore, ATTRwt is a disease of older population and neuromuscu-
lar complications are likely overshadowed by other medical comorbidities specially 
heart disease [78], and therefore the effect of disease modifying treatments would be 
difficult to assess.
5. Conclusions
Familial amyloid polyneuropathy is a rare, but treatable cause of neuropathy, 
diagnosis in an early stage is essential to establish disease modifying treatment 
at a stage which the disability can be prevented from progression or potentially 
reversed. Diagnosis should be suspected when red-flag symptomatology is present 
in a patient with neuropathy; and can possibly be established by sequencing of 
transthyretin gene. Musculoskeletal disease such as carpal tunnel syndrome and 
spinal stenosis are early manifestations and underdiagnosed causes of wild-type 
transthyretin amyloidosis. Increased cardiac uptake on nuclear imaging studies is 
a sensitive, widely available diagnostic modality for early diagnosis of familial and 
wild-type transthyretin amyloidosis.
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